CN103338790B - 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物 - Google Patents

用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物 Download PDF

Info

Publication number
CN103338790B
CN103338790B CN201280003243.XA CN201280003243A CN103338790B CN 103338790 B CN103338790 B CN 103338790B CN 201280003243 A CN201280003243 A CN 201280003243A CN 103338790 B CN103338790 B CN 103338790B
Authority
CN
China
Prior art keywords
sialin
peg
polyethylene glycol
derivatives
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280003243.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103338790A (zh
Inventor
李圣权
金源培
李瑟琪
金泰亨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D&d Medicine Ltd By Share Ltd
Original Assignee
Theraly Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraly Pharmaceuticals Inc filed Critical Theraly Pharmaceuticals Inc
Publication of CN103338790A publication Critical patent/CN103338790A/zh
Application granted granted Critical
Publication of CN103338790B publication Critical patent/CN103338790B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201280003243.XA 2011-06-28 2012-06-28 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物 Active CN103338790B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0062858 2011-06-28
KR1020110062858A KR101357117B1 (ko) 2011-06-28 2011-06-28 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
PCT/KR2012/005137 WO2013002580A2 (ko) 2011-06-28 2012-06-28 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
CN103338790A CN103338790A (zh) 2013-10-02
CN103338790B true CN103338790B (zh) 2018-01-23

Family

ID=47424684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280003243.XA Active CN103338790B (zh) 2011-06-28 2012-06-28 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物

Country Status (10)

Country Link
US (2) US20130217622A1 (https=)
EP (1) EP2727605B1 (https=)
JP (1) JP6084215B2 (https=)
KR (1) KR101357117B1 (https=)
CN (1) CN103338790B (https=)
AU (1) AU2012276478B2 (https=)
CA (1) CA2839410C (https=)
DK (1) DK2727605T3 (https=)
ES (1) ES2674581T3 (https=)
WO (1) WO2013002580A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN105985425B (zh) * 2014-12-11 2019-12-17 浙江海昶生物医药技术有限公司 一种聚乙二醇修饰的exendin类似物及其制备方法和应用
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
CN113456802A (zh) * 2015-12-29 2021-10-01 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물
WO2022212911A1 (en) * 2021-04-01 2022-10-06 Duke University Poegma copolymer conjugates and methods of treating diseases
WO2023028554A1 (en) 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection
KR20240155737A (ko) 2023-04-20 2024-10-29 전북대학교산학협력단 폴리에틸렌글리콜을 이용한 분자 전달 방법
EP4705331A1 (en) * 2023-05-01 2026-03-11 Neuraly Inc. Glucagon-like peptide-1 receptor agonist variants and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130066A1 (en) * 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
WO2010121559A1 (zh) * 2009-04-23 2010-10-28 派格生物医药(苏州)有限公司 新型exendin变体及其缀合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
CA2363712C (en) * 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2006042848A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
JP5096363B2 (ja) * 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
KR100890989B1 (ko) * 2006-06-01 2009-03-31 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
KR101112578B1 (ko) * 2009-07-16 2012-02-16 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130066A1 (en) * 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
WO2010121559A1 (zh) * 2009-04-23 2010-10-28 派格生物医药(苏州)有限公司 新型exendin变体及其缀合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics》;Tae Hyung Kim;《Bioconjugate Chemistry》;20110414;第22卷;摘要，图1 *

Also Published As

Publication number Publication date
WO2013002580A3 (ko) 2013-04-11
CA2839410C (en) 2019-05-14
JP6084215B2 (ja) 2017-02-22
KR20130008665A (ko) 2013-01-23
KR101357117B1 (ko) 2014-02-06
US20170189545A1 (en) 2017-07-06
ES2674581T3 (es) 2018-07-02
US10406230B2 (en) 2019-09-10
EP2727605A4 (en) 2014-12-24
EP2727605B1 (en) 2018-04-04
CA2839410A1 (en) 2013-01-03
CN103338790A (zh) 2013-10-02
WO2013002580A2 (ko) 2013-01-03
JP2014520798A (ja) 2014-08-25
EP2727605A2 (en) 2014-05-07
AU2012276478B2 (en) 2016-02-25
AU2012276478A1 (en) 2014-01-23
US20130217622A1 (en) 2013-08-22
DK2727605T3 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
CN103338790B (zh) 用聚乙二醇或其衍生物聚乙二醇化的唾液素‑4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物
TWI784914B (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
AU2015268199B2 (en) Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
EA018471B1 (ru) Слитые конструкции и конъюгаты лекарственного средства
CN110204617B (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
WO2012130015A1 (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
TW202014433A (zh) 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途
KR102394681B1 (ko) 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
JP2025178483A (ja) ポリペプチドを含む医薬組成物
KR100890989B1 (ko) 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
CN111194223A (zh) 与白蛋白具有较佳结合亲和力的药物分子
US12551541B2 (en) Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor
US11807672B2 (en) Conjugates of islet neogenesis peptides and analogs, and methods thereof
US20250152721A1 (en) Pharmaceutical composition containing pegylated exenatide variant and use thereof
TW202247856A (zh) 新穎之三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑及其用途
HK1230958A1 (en) Composition for treating diabetes, containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: THERALY

Free format text: FORMER OWNER: B + L DELIPHARM CORP.

Effective date: 20140926

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140926

Address after: American Maryland

Applicant after: THERALY Pharmaceuticals

Address before: Gyeonggi Do, South Korea

Applicant before: B&L Delipharm Corp.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180815

Address after: Gyeonggi Do, South Korea

Patentee after: D&D medicine Limited by Share Ltd

Address before: American Maryland

Patentee before: THERALY pharmaceuticals

TR01 Transfer of patent right